-
Media ReleaseNovartis announces long-term, relapse-free survival benefit for high-risk, stage III melanoma patients treated with Tafinlar® + Mekinist® following surgery
-
Media ReleaseNovartis announces new late-breaking ofatumumab data at EAN underscoring commitment to advancing treatment of relapsing forms of multiple sclerosis (RMS)
-
Media ReleaseNovartis Kisqali® shows overall survival benefit in HR+/HER2- advanced breast cancer with consistent findings in patients with more aggressive disease
-
Media ReleaseNovartis announces FDA approval of MET inhibitor Tabrecta™ for metastatic non-small cell lung cancer with METex14
-
Media ReleaseNovartis US Foundation supports telehealth programs to provide access to care for New Jersey's most vulnerable communities
-
Media ReleaseNovartis new analysis further showed durable and potent LDL-C reduction with inclisiran, an investigational first-in-class siRNA cholesterol-lowering treatment
-
Media ReleaseNovartis announces MET inhibitor capmatinib (INC280), the first potential treatment for METex14 mutated advanced non-small cell lung cancer, granted priority FDA review
-
Media ReleasePublic-Private Collaboration Commits to Accelerate Access to Health Services in Africa, Reaching 1.7 Million People
-
Media ReleaseNovartis announces FDA filing acceptance of Xolair® (omalizumab) for treatment of nasal polyps
-
Media ReleaseNovartis Kymriah® demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting
-
Media ReleaseNew Novartis medicine Adakveo® (crizanlizumab-tmca) approved by FDA to reduce frequency of pain crises in individuals living with sickle cell disease
-
Media ReleaseNovartis launches PsO at Work with music icon Cyndi Lauper to bring to life the impact psoriasis can have in the workplace